These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2345079)

  • 1. Atherosclerosis, peripheral arterial disease and the vascular response to ketanserin.
    Janicek M; Grassi CJ; Meyerovitz M; Callahan MB; Sandor T; Whittemore A; Mannick J; Harrington DP; Hollenberg NK
    Invest Radiol; 1990 May; 25(5):495-503. PubMed ID: 2345079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial response to ketanserin and aspirin in patients with advanced peripheral atherosclerosis.
    Janicek MJ; Meyerovitz M; Harrington DP; Hollenberg NK
    Invest Radiol; 1992 Jun; 27(6):415-21. PubMed ID: 1607256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of thrombosis and vasospasm in peripheral vascular disease.
    Hollenberg NK
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S21-8. PubMed ID: 1717769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
    BMJ; 1989 Feb; 298(6671):424-30. PubMed ID: 2495049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collateral arterial tree and responses to serotonin.
    Hollenberg NK
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S35-8. PubMed ID: 2446067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional vascular effects of serotonin and ketanserin in young, healthy subjects.
    Blauw GJ; van Brummelen P; Chang PC; Vermeij P; van Zwieten PA
    Hypertension; 1988 Mar; 11(3):256-63. PubMed ID: 2832328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related effects of 5-HT2 antagonists.
    Doyle AE
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S29-34. PubMed ID: 1717770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra arterial ketanserin in peripheral vascular disease.
    Boas RA
    Angiology; 1986 Apr; 37(4):267-71. PubMed ID: 2940946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.
    Majid PA; Morris WM; Sole MJ
    Can J Cardiol; 1987 Mar; 3(2):70-4. PubMed ID: 3567710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin].
    Mollo P
    Clin Ter; 1991 Apr; 137(2):113-5. PubMed ID: 1828404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or alpha 1-adrenergic receptors.
    Blauw GJ; van Brummelen P; Doorenbos CJ; van der Velde EA; van Zwieten PA
    Clin Pharmacol Ther; 1991 Apr; 49(4):377-84. PubMed ID: 1849810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large and small vessel responses to serotonin in the peripheral circulation.
    Hollenberg NK
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S89-91. PubMed ID: 2412068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
    De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
    Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation.
    Hollenberg NK; Nie Q
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S36-9. PubMed ID: 1369716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication.
    Walden R; Bass A; Rabi I; Adar R
    J Cardiovasc Surg (Torino); 1991; 32(6):737-40. PubMed ID: 1752890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperaemia of the calf after arterial reconstruction for lower limb atherosclerosis. A study with mercury strain gauge plethysmography.
    Kroese A
    Acta Chir Scand; 1975; 141(2):104-8. PubMed ID: 1154964
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.